Robb Knie Acquires 25,000 Shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) Stock

Hoth Therapeutics, Inc. (NASDAQ:HOTH) CEO Robb Knie purchased 25,000 shares of the business’s stock in a transaction on Friday, August 16th. The stock was bought at an average cost of $0.67 per share, with a total value of $16,750.00. Following the purchase, the chief executive officer now owns 58,131 shares in the company, valued at $38,947.77. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Hoth Therapeutics Stock Performance

Shares of HOTH opened at $0.68 on Wednesday. The firm has a market cap of $3.65 million, a price-to-earnings ratio of -0.35 and a beta of 0.80. Hoth Therapeutics, Inc. has a fifty-two week low of $0.58 and a fifty-two week high of $3.37. The firm has a 50 day moving average price of $0.82 and a 200-day moving average price of $1.11.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics in a research note on Friday, August 16th.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.